PHARMACEUTICAL EXECUTIVE NEWSLETTER

In this ISSUE

FDA Highlights “Flexibility” in Approving Rare Disease Therapies

The Evolution of Regulatory Operations

Data Analytics: Strength — and Solutions — in Numbers

Top Story

Is More Competition the Cure in the Pricing Debate?

Policymakers, payers and pharma companies weigh strategies for rationalizing drug prices. Jill Wechsler reports
… /Read more/

Read this Front & Center article to see how your Hub can be a Secret Weapon to improve Outcomes.

Learn more

Event

Prix Galien Honors “Discoveries of the Decade”

Novartis and Bristol-Myers Squibb were among the companies honored with Prix Galien Foundation “Discovery of the Decade” Awards in New York last week
… /Read more/

How the Life Sciences Cloud Coalition Is Driving Greater Innovation and Collaboration for Sponsors
Live Webinar: Tuesday, November 15 at 11:00am EST

Learn more

R&D

Biosimilar Trials Differ Notably from Innovator Studies

FDA officials agree that large comparative clinical trials defeat the purpose of the abbreviated development program for biosimilars
… /Read more/

Achieving Success in the Biosimilar Market
On Demand

Learn more

England to Selectively Accelerate Innovation

Leela Barham looks at the 18 recommendations of England's Accelerated Access Review (AAR), which proposes how to speed up adoption of the best innovation in the NHS
… /Read more/

Supporting internal and external decision-making through effective MSL activities
On Demand

Learn more

Calendar

/ December 13–14: Life Sciences Trade and Channel Strategies /

Philadelphia, PA

/ February 08–09, 2017: Speaker Programs 2017 /

Philadelphia, PA

/ March 14–16, 2017: eyeforpharma Barcelona 2017 /

Barcelona, Spain

/ April 26-28, 2017: CBI's 14^th Annual Pharmaceutical Compliance Congress /

WASHINGTON, DC

/ June 6–7, 2017: Pharmaceutical Compliance Congress Canada /

Toronto, Canada

Industry update

//Doug Noland was named Executive Director of Astellas's (Northbrook, IL) Patient Experience Organization.//Skin Sciences (Horsham, PA) named Frank McCaney as the President and Chief Executive Officer.//Mateon Therapeutics (South San Francisco, CA) announced the appointment of two new members to its board of directors: Donald R. Reynolds and Bobby W. Sandage, Jr., Ph.D. //

advertise with us / print subscribe / digital subscribe / visit pharmexec.com